Plasma triglycerides and type III hyperlipidemia are independently associated with premature familial coronary artery disease

Journal of the American College of Cardiology

Volumn 45, Issue 7, 2005, Pages 1003-1012

  Hopkins, Paul N ^a,c   Wu, Lily L ^a,b   Hunt, Steven C ^a   Brinton, Eliot A ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b ARUP LABORATORIES   (United States)

^c UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; DISEASE ASSOCIATION; FAMILIAL DISEASE; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERLIPIDEMIA; LIPID ANALYSIS; MALE; METABOLIC SYNDROME X; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; ONSET AGE; PRIORITY JOURNAL; RECOGNITION; RELATIVE; TRIACYLGLYCEROL BLOOD LEVEL; ULTRACENTRIFUGATION;

EID: 15944403233     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2004.11.062     Document Type: Article

References (67)

1. J.E. Hokanson, M.A. Austin Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies J Cardiovasc Risk 3 1996 213 219
2. M. Miller, A. Seidler, A. Moalemi, T.A. Pearson Normal triglyceride levels and coronary artery disease events: the Baltimore Coronary Observational Long-Term Study J Am Coll Cardiol 31 1998 1252 1257
3. L.E. Eberly, J. Stamler, J.D. Neaton Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease Arch Intern Med 163 2003 1077 1083
4. W.P. Castelli The triglyceride issue: a view from Framingham Am Heart J 112 1986 432 437
5. D.M. Lloyd-Jones, C.J. O'Donnell, R.B. D'Agostino, J. Massaro, H. Silbershatz, P.W. Wilson Applicability of cholesterol-lowering primary prevention trials to a general population: the Framingham heart study Arch Intern Med 161 2001 949 954
6. A.R. Sharrett, C.M. Ballantyne, S.A. Coady Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk In Communities (ARIC) study Circulation 104 2001 1108 1113
7. P. Schnohr, J.S. Jensen, H. Scharling, B.G. Nordestgaard Coronary heart disease risk factors ranked by importance for the individual and community A 21-year follow-up of 12 000 men and women from the Copenhagen City Heart Study Eur Heart J 23 2002 620 626
8. L.A. Carlson, L.E. Bottiger, P.E. Ahfeldt Risk factors for myocardial infarction in the Stockholm Prospective Study: a 14 year follow-up focusing on the role of plasma triglycerides and cholesterol Acta Med Scand 206 1979
9. J. Jeppesen, H.O. Hein, P. Suadicani, F. Gyntelberg Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study Circulation 97 1998 1029 1036
10. G. Assmann, P. Cullen, H. Schulte Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study Circulation 105 2002 310 315
11. J.J. Genest, S.S. Martin-Munley, J.R. McNamara Familial lipoprotein disorders in patients with premature coronary artery disease Circulation 85 1992 2025 2033
12. R.R. Williams, P.N. Hopkins, S.C. Hunt Population-based frequency of dyslipidemia syndromes in coronary prone families in Utah Arch Intern Med 150 1990 582 588
13. G. Assmann, H. Schulte Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience) Am J Cardiol 70 1992 733 737
14. V. Manninen, L. Tenkanen, P. Koskinen Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki heart study Implications for treatment Circulation 85 1992 37 45
15. B.H. Greenberg, W.C. Blackwelder, R.I. Levy Primary type V hyperlipoproteinemia A descriptive study in 32 families Ann Intern Med 87 1977 526 534
16. S. Malekzadeh, F.A. Dressler, J.M. Hoeg, H.B. Brewer, W.C. Roberts Left atrial endocardial lipid deposits and absent to minimal arterial lipid deposits in familial hyperchylomicronemia Am J Cardiol 67 1991 1431 1434
17. D.S. Fredrickson, J. Morganroth, R.I. Levy Type III hyperlipoproteinemia: an analysis of two contemporary definitions Ann Intern Med 82 1975 150 157
18. J. Morganroth, R.I. Levy, D.S. Fredrickson The biochemical, clinical, and genetic features of type III hyperlipoproteinemia Ann Intern Med 82 1975 158 174
19. P.N. Hopkins, G. Heiss, R.C. Ellison Coronary artery disease risk in familial combined hyperlipidemia and familial hypertriglyceridemia: a case-control comparison from the National Heart, Lung, and Blood Institute Family Heart Study Circulation 108 2003 519 523
20. J.K. Ninomiya, G. L'Italien, M.H. Criqui, J.L. Whyte, A. Gamst, R.S. Chen Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey Circulation 109 2004 42 46
21. G. Schillaci, M. Pirro, G. Vaudo Prognostic value of the metabolic syndrome in essential hypertension J Am Coll Cardiol 43 2004 1817 1822
22. D.I. Thompson, C. Sirio, P. Holt The strategic use of outcome information Jt Comm J Qual Improv 26 2000 576 586
23. S.C. Hunt, R.R. Williams, G.K. Barlow A comparison of positive family history definitions for defining risk of future disease J Chron Dis 39 1986 809 821
24. R.R. Williams, S.C. Hunt, G.K. Barlow Health Family Trees: a tool for finding and helping young family members of coronary and cancer prone pedigrees in Texas and Utah Am J Public Health 78 1988 1283 1286
25. M. Higgins, M. Province, G. Heiss NHLBI Family Heart Study: objectives and design Am J Epidemiol 143 1996 1219 1228
26. Lipid Research Clinics Manual of laboratory operations: Lipid Research Clinics Program 1974 National Institutes of Health, Report No.: DHEW publication NIH Bethesda, MD 1:75-628
27. L.L. Wu, G.R. Warnick, J.T. Wu, R.R. Williams, J.M. Lalouel A rapid micro-scale procedure for determination of the total lipid profile Clin Chem 35 1989 1486 1491
28. 2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol Clin Chem 28 1982 1379 1388
29. Adult Treatment Panel III Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report Circulation 106 2002 3143 3421
30. J.W. Yarnell, C.C. Patterson, P.M. Sweetnam Do total and high density lipoprotein cholesterol and triglycerides act independently in the prediction of ischemic heart disease? Ten-year follow-up of Caerphilly and Speedwell cohorts Arterioscler Thromb Vasc Biol 21 2001 1340 1345
31. M.J. Stampfer, R.M. Krauss, J. Ma A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction JAMA 276 1996 882 888
32. A. Fontbonne, E. Eschwege, F. Cambien Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes Diabetologia 1989 300 304
33. P. Lindquist, C. Bengtsson, L. Lissner, C. Bjorkelund Cholesterol and triglyceride concentration as risk factors for myocardial infarction and death in women, with special reference to influence of age J Intern Med 251 2002 484 489
34. M.A. Austin, J.E. Hokanson, K.L. Edwards Hypertriglyceridemia as a cardiovascular risk factor Am J Cardiol 81 1998 7B 12B
35. R.W. Mahley, S.C. Rall Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism C.R. Scriver A.L. Beaudet W.S. Sly D. Valle The Metabolic and Molecular Bases of Inherited Disease 8th edition 2001 McGraw Hill, Inc. New York, NY 2835 2862
36. P. Borrie Type 3 hyperlipoproteinaemia Br Med J 2 1969 665 667
37. W.R. Hazzard, T.F. O'Donnell, Y.L. Lee Broad-beta disease (type III hyperlipoproteinemia) in a large kindred Evidence for a monogenic mechanism Ann Intern Med 82 1975 141 149
38. M.A. Mishkel, D.J. Nazir, S. Crowther A longitudinal assessment of lipid ratios in the diagnosis of type III hyperlipoproteinaemia Clin Chim Acta 58 1975 121 136
39. P.M. Stuyt, A. Van't Laar Clinical features of type III hyperlipoproteinaemia Neth J Med 26 1983 104 111
40. G. Feussner, A. Wagner, B. Kohl, R. Ziegler Clinical features of type III hyperlipoproteinemia: analysis of 64 patients Clin Invest 71 1993 362 366
41. W. Marz, G. Feussner, R. Siekmeier Apolipoprotein E to B ratio: a marker for type III hyperlipoproteinaemia Eur J Clin Chem Clin Biochem 31 1993 743 747
42. J. Dobmeyer, J. Lohrmann, G. Feussner Prevalence and association of atherosclerosis at three different arterial sites in patients with type III hyperlipoproteinemia Atherosclerosis 119 1996 89 98
43. J.C. LaRosa, L.E. Chambless, M.H. Criqui Patterns of dyslipoproteinemia in selected North American populations The Lipid Research Clinics Program Prevalence Study Circulation 73 1986 1 12
44. W. Hazzard, J. Goldstein, H. Schrott Hyperlipidemia in coronary heart disease III. Evaluation of lipoprotein phenotypes of 156 genetically defined survivors of myocardial infarction J Clin Invest 52 1973 1569 1577
45. J.S. Cohn, C. Marcoux, J. Davignon Detection, quantification, and characterization of potentially atherogenic triglyceride-rich remnant lipoproteins Arterioscler Thromb Vasc Biol 19 1999 2474 2486
46. E.J. Schaefer, M.C. Audelin, J.R. McNamara Comparison of fasting and postprandial plasma lipoproteins in subjects with and without coronary heart disease Am J Cardiol 88 2001 1129 1133
47. J. Bjorkegren, A. Silveira, S. Boquist Postprandial enrichment of remnant lipoproteins with apoC-I in healthy normolipidemic men with early asymptomatic atherosclerosis Arterioscler Thromb Vasc Biol 22 2002 1470 1474
48. A. Onat, G. Hergenc, V. Sansoy Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders Atherosclerosis 168 2003 81 89
49. B.G. Nordestgaard, D.B. Zilversmit Large lipoproteins are excluded from the arterial wall in diabetic cholesterol-fed rabbits J Lipid Res 29 1988 1491 1500
50. M.C. Corti, M.E. Salive, J.M. Guralnik Serum albumin and physical function as predictors of coronary heart disease mortality and incidence in older persons J Clin Epidemiol 49 1996 519 526
51. J.J. Nelson, D. Liao, A.R. Sharrett Serum albumin level as a predictor of incident coronary heart disease: the Atherosclerosis Risk In Communities (ARIC) study Am J Epidemiol 151 2000 468 477
52. M. Saito, T. Ishimitsu, J. Minami, H. Ono, M. Ohrui, H. Matsuoka Relations of plasma high-sensitivity C-reactive protein to traditional cardiovascular risk factors Atherosclerosis 167 2003 73 79
53. H.A. Schwertner, W.G. Jackson, G. Tolan Association of low serum concentration of bilirubin with increased risk of coronary artery disease Clin Chem 40 1994 18 23
54. P.N. Hopkins, L.L. Wu, S.C. Hunt, B.C. James, G.M. Vincent, R.R. Williams Higher serum bilirubin is associated with decreased risk for early familial coronary artery disease Arterioscler Thromb Vasc Biol 16 1996 250 255
55. H.A. Schwertner Association of smoking and low serum bilirubin antioxidant concentrations Atherosclerosis 136 1998 383 387
56. F. Kronenberg, H. Coon, A. Gutin A genome scan for loci influencing anti-atherogenic serum bilirubin levels Eur J Hum Genet 10 2002 539 546
57. R.S. Rosenson Myocardial injury: the acute phase response and lipoprotein metabolism J Am Coll Cardiol 22 1993 933 940
58. R. Carlsson, G. Lindberg, L. Westin, B. Israelsson Serum lipids four weeks after acute myocardial infarction are a valid basis for lipid lowering intervention in patients receiving thrombolysis Br Heart J 74 1995 18 20
59. C. Fresco, A.P. Maggioni, S. Signorini Variations in lipoprotein levels after myocardial infarction and unstable angina: the LATIN trial Ital Heart J 3 2002 587 592
60. C.A. Sueta, M. Chowdhury, S.J. Boccuzzi Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease Am J Cardiol 83 1999 1303 1307
61. T.A. Pearson, I. Laurora, H. Chu, S. Kafonek The Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals Arch Intern Med 160 2000 459 467
62. J.J. Rohlfing, J.D. Brunzell The effects of diuretics and adrenergic-blocking agents on plasma lipids West J Med 145 1986 210 218
63. B.L. Kasiske, J.Z. Ma, R.S. Kalil, T.A. Louis Effects of antihypertensive therapy on serum lipids Ann Intern Med 122 1995 133 141
64. R.H. Grimm, J.M. Flack, G.A. Grandits Long-term effects on plasma lipids of diet and drugs to treat hypertension JAMA 275 1996 1549 1556
65. P.J. Savage, S.L. Pressel, J.D. Curb Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension Arch Intern Med 158 1998 741 751
66. M.R. Lakshman, D.J. Reda, B.J. Materson, W.C. Cushman, E.D. Freis Diuretics and beta-blockers do not have adverse effects at 1 year on plasma lipid and lipoprotein profiles in men with hypertension Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents Arch Intern Med 159 1999 551 558
67. R.R. Williams, S.C. Hunt, G. Heiss Usefulness of cardiovascular family history data for population-based preventive medicine and medical research (The Health Family Tree Study and the NHLBI Family Heart Study) Am J Cardiol 87 2001 129 135